Keeping an M&A score? Here's the Big Pharma lineup, pre-megadeal

With so much M&A in the air, the lineup of top pharma companies will no doubt rearrange. Pfizer ($PFE), for one, would regain the No. 1 spot if it succeeds in buying AstraZeneca ($AZN). Merck's ($MRK) consumer health deal and planned drug-brand sale, GlaxoSmithKline ($GSK) and Novartis' ($NVS) swap-and-shop--they'll all force a market-value shuffle. So just for the record, which are the top drugmakers by market value today? Johnson & Johnson ($JNJ) ($282.9 billion), Roche ($RHHBY) ($244.6 billion) and Novartis ($214.5 billion). Pfizer comes in fourth, with $191.2 billion. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.